Home / News / Retatrutide Vs Tirzepatide: Weight Loss Results, Safety, And FDA Approval

Retatrutide Vs Tirzepatide: Weight Loss Results, Safety, And FDA Approval

Views: 249     Author: Rchemsell     Publish Time: 2026-11-18      Origin: Site

Inquire

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Content Menu

● How Retatrutide and Tirzepatide Work

● What the Weight Loss Trials Actually Found

>> Retatrutide: From Phase 2 to the TRIUMPH Program

>> Tirzepatide: Why SURMOUNT-1 Has Two Widely Quoted Numbers

● How to Compare Weight Loss Results Without Overstating Them

● What TRIUMPH-5 Can Tell Us That Separate Trials Cannot

● Approval, Side Effects, and Research-Use Claims

● What a Peptide Certificate of Analysis Can and Cannot Show

● Frequently Asked Questions

>> 1. Is retatrutide better than tirzepatide for weight loss?

>> 2. Is retatrutide FDA approved?

>> 3. Are Mounjaro and Zepbound the same drug?

>> 4. Why do articles cite both 20.9% and 22.5% for tirzepatide?

>> 5. Does triple agonism mean retatrutide has more side effects?

● References

Retatrutide vs tirzepatide is not a contest you can settle by comparing two weight loss percentages. Tirzepatide is an FDA-approved prescription drug for specific uses. Retatrutide is an investigational drug that has shown substantial weight reduction in clinical trials but is not FDA approved as of November 18, 2026. A randomized trial designed to compare them directly, TRIUMPH-5, is registered, but public head-to-head results were not available at this review.

That distinction matters whether you are evaluating a headline, reviewing a metabolic research program, or reading a supplier's peptide specification. A clinical trial tells you what happened in a defined population. A prescribing label tells you what a regulator has approved and under what conditions. A batch report tells you what was measured in a particular lot. Those documents answer different questions.

Retatrutide and Tirzepatide Receptor Targets

How Retatrutide and Tirzepatide Work

Tirzepatide activates two receptors: GIP and GLP-1. Retatrutide activates those same two receptors plus the glucagon receptor. An agonist activates a receptor, triggering a biological response. "Dual" and "triple" describe the number of receptor targets, not the strength of the drug or the quality of the clinical evidence.

Comparison Retatrutide Tirzepatide
Receptor targets GIP, GLP-1, and glucagon GIP and GLP-1
Development and approval Investigational; not FDA approved FDA-approved prescription products include Mounjaro and Zepbound
Selected weight loss findings 24.2% mean reduction at 48 weeks in a phase 2 group; up to 28.7% at 68 weeks in a sponsor-reported phase 3 analysis 20.9% mean reduction at 72 weeks in the highest-dose SURMOUNT-1 group under the treatment-regimen analysis
Direct comparison TRIUMPH-5 compares both drugs in the same randomized study Public comparative results were not available at this review

GIP and GLP-1 signaling is relevant to glucose regulation, and GLP-1 also plays a role in appetite. Adding glucagon receptor activity gives researchers another pathway to investigate. It does not, by itself, establish how much weight change comes from that pathway or prove a clinical advantage over tirzepatide. The drugs are different molecules, not two otherwise identical treatments that differ only by one receptor target.

What the Weight Loss Trials Actually Found

Retatrutide: From Phase 2 to the TRIUMPH Program

The peer-reviewed phase 2 retatrutide trial enrolled 338 adults with obesity, or overweight with a weight-related condition, without diabetes. At week 48, the highest-dose group had an estimated mean body weight reduction of 24.2%, compared with 2.1% in the placebo group. That result established a reason to investigate further. It was not a comparison against tirzepatide.

Retatrutide has since advanced beyond phase 2 evidence. In the phase 3 TRIUMPH-4 study, which enrolled adults with obesity or overweight and knee osteoarthritis, the sponsor reported up to 28.7% mean weight reduction at 68 weeks under an analysis estimating the effect if participants remained on assigned treatment. The study also evaluated knee pain. Its findings are informative for a population with knee osteoarthritis, but its weight result should not be treated as an estimate for every population with obesity.

Tirzepatide: Why SURMOUNT-1 Has Two Widely Quoted Numbers

SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes. At 72 weeks, the highest-dose tirzepatide group had a mean body weight reduction of 20.9% under the treatment-regimen analysis, compared with 3.1% for placebo.

The same trial also reported 22.5% for that tirzepatide group under a different analysis. An estimand defines the treatment effect an analysis aims to estimate, including how it handles events such as stopping treatment. The treatment-regimen estimate addresses the effect regardless of whether participants discontinued treatment. The efficacy estimate addresses what the effect would be if participants remained on their assigned treatment. Both figures can be valid, but they do not answer the same question.

How to Compare Weight Loss Results Without Overstating Them

Before putting two trial results in the same chart or presentation, check four things:

1. Who enrolled? Look for differences in diabetes status, baseline body weight, and conditions such as knee osteoarthritis. A result in one study population may not carry over to another.

2. When was the outcome measured? A result at 48 weeks and one at 72 weeks are not measurements at the same point in treatment. Dividing each result by its follow-up time does not establish which drug works faster.

3. What did the analysis estimate? Check how each study handled treatment discontinuation and missing measurements. Avoid pairing an on-treatment-style estimate for one drug with an estimate that accounts for discontinuation for the other and calling it a fair comparison.

4. What was the comparator? Randomization supports comparisons between groups within a trial. It does not randomize participants across two separate trials. A placebo group in each study does not erase differences in enrollment, follow-up, or trial conduct.

For example, subtracting 20.9% from 28.7% gives 7.8 percentage points. The arithmetic is correct, but the interpretation "retatrutide causes 7.8 percentage points more weight loss" is not. The figures come from different populations, at different time points, under different analysis assumptions. Use them to describe each trial, not to calculate a treatment advantage.

What TRIUMPH-5 Can Tell Us That Separate Trials Cannot

TRIUMPH-5 is a phase 3, randomized, double-blind study comparing retatrutide with tirzepatide in adults with obesity. Its registry lists percent change in body weight at week 80 as the primary outcome. Because both groups are studied under the same protocol, the trial is designed to give a more direct answer about comparative weight loss than two placebo-controlled studies conducted separately.

When the results become available, look beyond which group has the larger average. Read the estimated between-group difference and its confidence interval, which describes the estimate's precision. Check how many participants discontinued, how missing outcomes were handled, and whether side effects led people to stop. A difference in mean weight loss does not, on its own, settle whether the overall benefit–risk balance is better.

The endpoints also set limits on what the trial can establish. A difference in body weight at week 80 is not automatically evidence of fewer heart attacks, better kidney outcomes, or a benefit that persists after treatment ends. Those questions deserve evidence that measures those outcomes directly.

Separate Trials and Direct Comparison

Approval, Side Effects, and Research-Use Claims

In the United States, tirzepatide was first approved as Mounjaro in 2022 for type 2 diabetes. Zepbound was first approved in 2023 for chronic weight management in eligible adults and gained an indication in 2024 for moderate to severe obstructive sleep apnea in adults with obesity. Check the current label for the relevant product rather than assuming the brand names have identical indications.

Gastrointestinal events such as nausea, diarrhea, and vomiting have been reported in trials of both drugs. Rates from separate studies cannot reliably tell you which is better tolerated. The retatrutide phase 2 trial also reported a dose-related increase in heart rate that peaked at week 24 and declined thereafter. Zepbound's prescribing information includes a boxed warning about the potential risk of thyroid C-cell tumors; whether it causes these tumors in humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.

Retatrutide remains investigational. The FDA says it cannot be used in compounding under U.S. federal law. A vial marked "research use only" does not become an approved treatment, and an online seller's purity claim cannot establish safety for human use. This article is not a guide to dosing, combining, or switching medicines. Patients considering a treatment change should discuss approved options with a licensed clinician.

Peptide Batch Documentation Review

What a Peptide Certificate of Analysis Can and Cannot Show

For legitimate laboratory or cosmetic ingredient projects, review the certificate of analysis (CoA) against the intended use and the exact lot number. If purity is reported as an HPLC peak-area percentage, it describes the relative chromatographic signal under the stated test conditions. It is not necessarily the peptide's mass fraction in a vial. Nor does a purity figure alone establish molecular identity, biological activity, sterility, or suitability for an end use.

Start with three procurement questions:

- Does the report match the lot? Check that the lot number on the document matches the packaging and that the report identifies the material tested.

- How were identity and purity assessed? Ask what method was used for each, what the result means, and which acceptance criteria applied. An identity result and a chromatographic purity result are not interchangeable.

- What does the intended application require? Define the documentation, packaging, and acceptance criteria before ordering. A laboratory specification is not a cosmetic safety assessment, and neither substitutes for pharmaceutical approval.

Rchemsell is a China-based peptide manufacturer serving laboratory research and cosmetic industry customers. Its stated services include custom peptide synthesis, OEM and ODM support, quality testing, lyophilized packaging, and shipping. The company reports a purity range of 98%–99%; buyers should verify the result and method for the specific lot rather than treating that range as a universal specification.

Frequently Asked Questions

1. Is retatrutide better than tirzepatide for weight loss?

Separate retatrutide studies have reported numerically greater mean reductions than SURMOUNT-1, but that does not establish superiority. TRIUMPH-5 is designed to compare the drugs directly. Its results were not publicly available at this review.

2. Is retatrutide FDA approved?

No. As of November 18, 2026, retatrutide remains investigational in the United States. Positive phase 3 findings do not themselves grant marketing approval.

3. Are Mounjaro and Zepbound the same drug?

Both contain tirzepatide, but they are distinct prescription products with different labeled indications. The current label for the relevant brand is the reference for approved uses, contraindications, and warnings.

4. Why do articles cite both 20.9% and 22.5% for tirzepatide?

Both figures describe the highest-dose group in SURMOUNT-1 at week 72. The 20.9% figure comes from the treatment-regimen analysis, while 22.5% comes from an efficacy analysis that estimates the effect if participants remained on assigned treatment.

5. Does triple agonism mean retatrutide has more side effects?

Not necessarily. Receptor count does not establish tolerability. Compare adverse-event rates, severity, and discontinuations under the same trial conditions before drawing a comparative conclusion.

References

1. PSPeptides Research Team. [The Best Proven Guide to Retatrutide vs Tirzepatide 2026]. Original article reviewed for topic coverage and claims requiring correction. [pspeptides]

2. Jastreboff AM, et al. [Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial]. New England Journal of Medicine, 2023. Phase 2 population, body weight outcomes, and safety findings. [nejm]

3. Jastreboff AM, et al. [Tirzepatide Once Weekly for the Treatment of Obesity]. New England Journal of Medicine, 2022. SURMOUNT-1 design, weight outcomes, and analyses. [clinicaltrials]

4. Eli Lilly and Company. [ObesityWeek 2026 Clinical Data Announcement]. Sponsor-reported retatrutide phase 3 updates. [apnews]

5. Pharmaphorum. [Lilly's Obesity Triple Pulls Off 29% Weight Loss in Trial]. Coverage of the sponsor-reported TRIUMPH-4 population and week-68 result. [pharmaphorum]

6. ClinicalTrials.gov. [TRIUMPH-5: Retatrutide Compared With Tirzepatide in Adults With Obesity]. Trial registration, design, and prespecified outcomes. [clinicaltrials]

7. U.S. Food and Drug Administration. [Mounjaro Approval Package], [Zepbound Prescribing Information], and [Obstructive Sleep Apnea Approval Announcement]. U.S. approval history, indications, and safety information. [accessdata.fda]

8. U.S. Food and Drug Administration. [FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss]. Retatrutide's regulatory status, compounding restrictions, and unapproved product concerns. [fda]

QUICK LINKS

PRODUCTS

CONTACT
  400‑869‑432
Copyright © Rchemsell. All Rights Reserved. Website: www.rchemsell.com. Sitemap  | Privacy Policy | Terms of Service | Return & Refund Policy